Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose intranasal Memogain study in healthy elderly volunteers
NL-OMON43526Active, not recruiting
- Sponsor
- Neurodyn Life Sciences Inc.
- Start
- Mar 2016
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of benzgalantamine in Alzheimer's disease (AD) and Dementia (3 arms), sponsored by Neurodyn Life Sciences Inc. Primary endpoints: Treatment-emergent adverse events, Vital sign abnormalities and 12 more. Started Mar 2016; status: active, not recruiting.
02
Drugs
benzgalantamine
03
Conditions
Alzheimer's disease (AD)Dementia
Beyond the preview
Go deeper on NL-OMON43526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43526.